Ironwood Pharmaceuticals IRWD Stock Issuance Proceeds
Stock Issuance Proceeds at other companies
Other financials
Where this comes from
Reported directly by Ironwood Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions.
The official record: Ironwood Pharmaceuticals’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ironwood Pharmaceuticals's stock issuance proceeds.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ironwood Pharmaceuticals's stock issuance proceeds?
- Ironwood Pharmaceuticals (IRWD) reported stock issuance proceeds of $122K in Q4 2025.
- How has Ironwood Pharmaceuticals's stock issuance proceeds changed year-over-year?
- Ironwood Pharmaceuticals's stock issuance proceeds decreased by 39.9% year-over-year, from $203K to $122K.
- What is the long-term trend for Ironwood Pharmaceuticals's stock issuance proceeds?
- Over 4 years (2021 to 2025), Ironwood Pharmaceuticals's stock issuance proceeds has grown at a -67.6% compound annual growth rate (CAGR), from $19.58M to $216K.
- What does stock issuance proceeds mean?
- Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.